The Moderna vaccine’s efficacy declines a year after first administered for those who received the shot early in the rollout, compared to protection in recently vaccinated people, the company announced Wednesday.
A Moderna cited clinical trial data that shows breakthrough infections are less common among participants approximately eight months after receiving the first dose compared to approximately 13 months, Axios reported.
Moderna’s findings were based on a phase 3 clinical trial that examined breakthrough cases from July to August 2021. Axios reported the study documented 162 breakthrough cases in the particular group vaccinated over a year ago, while only 88 occurred in the group inoculated during the early part of the year.
Moderna’s push for booster shots comes as the Biden administration wants to offer people a second dose eight months after the first, starting later this month. However, there is disagreement among the medical professionals and leaders on the necessity of boosters.
Moderna CEO Stephane Bancel said waning immunity justifies the need for boosters while scientists, Axios reported.
FDA staffers in The Lancet medical journal said current vaccine supplies “could save more lives if used in previously unvaccinated populations than if used as boosters in vaccinated populations,” Axios reported.